Saturday 17 October 2026
Export ATYR’s income statement to Excel — free account
aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.17
0.01
−5.56%
Follow ATYR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 6.27 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (3.42) | |
P/B ratio |
— | — | — | 0.87 | |
Price to Tangible BV |
— | — | — | 0.87 | |
EV/Sales |
— | — | — | (1.50) | |
EV/EBITDA |
— | — | — | 0.21 | |
EV/Operating CF |
— | — | — | 0.27 | |
EV/FCF |
— | — | — | 0.27 | |
Quick Ratio |
5.08 | 5.73 | 5.25 | 5.82 | |
Current Ratio |
5.12 | 5.78 | 5.30 | 5.93 | |
Net Debt/EBITDA |
5.40 | 5.87 | 5.31 | 3.34 | |
Debt/Assets |
0.05% | 0.19% | 0.28% | 0.37% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.11 | |
Operating CF/Net income |
0.91 | 1.16 | 0.87 | 0.80 | |
Capex/Depreciation |
(0.28) | (0.99) | (0.58) | 0.30 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 11,647.37% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,528.95% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 687.89% | |
Graham Net Nets |
— | — | — | 0.95 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (115.28%) | |
Free Cash Flow Yield |
— | — | — | (90.07%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.13) | (0.13) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.13) | (0.13) | (0.21) | |
Cash per Share |
0.59 | 0.68 | 0.85 | 0.93 | |
Shareholders Equity per Share |
0.50 | 0.59 | 0.72 | 0.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.50 | 0.59 | 0.72 | 0.82 | |
Free Cash Flow |
(9.42) | (12.65) | (12.21) | (20.51) | |
Working Capital |
46.97 | 55.88 | 65.09 | 77.34 | |
Capital Expenditures |
(0.07) | (0.14) | (0.02) | (0.04) | |
Net Current Asset Value |
37.13 | 45.66 | 54.52 | 66.41 | |
EV/EBIT |
— | — | — | 0.21 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.19 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.46 | 0.73 | 1.30 | 1.44 | |
Average Payables |
3.56 | 2.14 | 4.11 | 4.01 | |
Average Assets |
85.68 | 88.45 | 94.92 | 99.13 | |
Average Common Equity |
61.63 | 66.30 | 68.56 | 72.59 |
Columns are period end dates